Efficacy and Safety of SR1375 in Adult Patients With CAP (CAP)

A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SR1375 in Hospitalized Adult Patients With Community-acquired Pneumonia

This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.

Study Overview

• Status: Recruiting
• Conditions: Community-acquired Pneumonia
• Intervention / Treatment: Drug: SR1375 capsule 3mg+regular treatments; Drug: SR1375 capsule 1mg+regular treatments; Drug: SR1375 capsule 0.3mg+regular treatments; Drug: Placebo capsule+regular treatments

Detailed Description

This is a randomized, double-blind and placebo-controlled phase 2 study comparing SR1375 with placebo in adult patients with CAP. It consists of a screening period, a double-blind treatment period, and a post-treatment safety follow-up period. Baseline NIAID-OS 8-point scale score will be checked for eligibility. Around 240 eligible subjects will be recruited and randomized into four arms at 1:1:1:1 ratio to receive SR1375 0.3mg, SR1375 1mg, SR1375 3mg or placebo orally daily for 56 days. Subjects, investigators, all clinical study site staffs, and the Sponsor will remain blinded to treatment assignment during the study. Subjects will receive regular treatments as per his/her condition by investigator. After completion of double-blind treatment period, subjects will continue to complete the safety follow-up for 14 days.

• Study Type: Interventional
• Enrollment (Estimated): 240
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Wang, PhD; Phone Number: (086)021-68161783; Email: fwang@simrbio.com

Study Locations

• China
  • Anhui
    • Fuyang, Anhui, China, 236001
      • Recruiting
      • Fuyang People's Hospital
  • Beijing
    • Beijing, Beijing, China, 100191
      • Recruiting
      • Peking University Third Hospital
  • Fujian
    • Zhangzhou, Fujian, China, 363000
      • Recruiting
      • Zhangzhou Hospital
  • Guangdong
    • Gaozhou, Guangdong, China, 525200
      • Recruiting
      • Gaozhou People's Hospital
    • Guangzhou, Guangdong, China, 510080
      • Recruiting
      • The First Affiliated Hospital of Sun Yat-Sen University
    • Guangzhou, Guangdong, China, 510630
      • Recruiting
      • The Third Affiliated Hospital of Southern Medical University
    • Guangzhou, Guangdong, China, 515399
      • Recruiting
      • Nanfang Hospital
    • Shantou, Guangdong, China, 515041
      • Recruiting
      • The First Affiliated Hospital of Shantou University Medical College
  • Guangxi
    • Yulin, Guangxi, China, 537000
      • Recruiting
      • Yulin First People's Hospital
  • Hebei
    • Shijiazhuang, Hebei, China, 050023
      • Recruiting
      • The First Hospital of Hebei Medical University
  • Heilongjiang
    • Daqing, Heilongjiang, China, 163000
      • Recruiting
      • Daqing People's Hospital
    • Daqing, Heilongjiang, China, 163000
      • Recruiting
      • Daqing Longnan Hospital
  • Henan
    • Shangqiu, Henan, China, 476100
      • Recruiting
      • Shangqiu People's Hospital
    • Zhengzhou, Henan, China, 450003
      • Recruiting
      • Henan Provincial People's Hospital
  • Hunan
    • Yueyang, Hunan, China, 414000
      • Recruiting
      • Yueyang Central Hospital
  • Jiangsu
    • Nanjing, Jiangsu, China, 210006
      • Withdrawn
      • Nanjing First Hospital
  • Jiangxi
    • Nanchang, Jiangxi, China, 330006
      • Recruiting
      • The First Affiliated Hospital of NanChang University
    • Nanchang, Jiangxi, China, 330006
      • Recruiting
      • Jiangxi Provincial People's Hospital
  • Jilin
    • Yanbian, Jilin, China, 133000
      • Withdrawn
      • Yanbian University Affiliated Hospital
  • Liaoning
    • Dalian, Liaoning, China, 116021
      • Recruiting
      • The Second Hospital of Dalian Medical University
    • Dalian, Liaoning, China, 116021
      • Recruiting
      • Dalian Central Hospital
  • Shandong
    • Weifang, Shandong, China, 261041
      • Recruiting
      • Weifang Second People's Hospital
    • Zibo, Shandong, China, 255100
      • Recruiting
      • Zibo Municipal Hospital
  • Shanghai
    • Shanghai, Shanghai, China, 200032
      • Recruiting
      • Zhongshan Hospital
    • Shanghai, Shanghai, China, 200433
      • Recruiting
      • Shanghai Pulmonary Hospital
    • Shanghai, Shanghai, China, 200335
      • Recruiting
      • Shanghai Tongren Hospital
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • Recruiting
      • West China Hospital of Sichuan University
      • Contact: Dan Liu, Doctor
    • Chengdu, Sichuan, China, 610500
      • Recruiting
      • The First Affiliated Hospital of Chengdu Medical College
  • Zhejiang
    • Lishui, Zhejiang, China, 323000
      • Recruiting
      • Lishui Central Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria:

• The subject or their legally acceptable representative (LAR) has voluntarily signed the informed consent form (ICF) prior to any study-related procedures, and the subject is willing and able to comply with all study requirements, restrictions, and procedures. If consent is provided by an LAR for a subject with limited or no capacity to consent, re-consenting may be performed if the subject regains capacity.
• Aged 18 to 85 years.
• Diagnosis of CAP
• Prior to screening, the subject has been receiving standard-of-care treatment for pneumonia in a medical institution, including at least 3 days of intravenous (IV) anti-infective therapy, with no clinical improvement.
• Chest CT showing multi-lobar infiltrates, and for subjects not receiving invasive mechanical ventilation, an oxygenation index (PaO2/FiO2 ratio) between 100 and 300 mmHg.
• Expected to require continued hospitalization for at least 7 days from the time of signing the ICF.
• Baseline NIAID-OS 8-point scale score of 5 points and transcutaneous oxygen saturation ≤ 93% without oxygen inhalation, 6 points or 7points. (5 points refer to hospitalization with oxygen therapy; 6 points refer to hospitalization with high flow oxygen therapy or non-invasive mechanical ventilation. 7 points refer to hospitalization with invasive mechanical ventilation).High oxygen flow refers to ≥ 4 L/min.)
• With ≥ 1 high risk factors including chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, type 2 diabetes, chronic kidney disease, coronary heart disease, age ≥ 65 years, moderate obesity (body mass index>32.5kg/m2), etc.
• Participants of women of childbearing potential(WOCBP) and male participants with WOCBP partners must agree to use one or more effective contraceptive methods during the treatment period and until 90 days after the last administration.

Key Exclusion Criteria:

• Patients who are currently receiving or are expected to require ECMO treatment within 24 hours.
• Presence of active tuberculosis (TB) or severe asthma.
• History of unstable angina or acute myocardial infarction within 3 months prior to screening, or stroke within 4 weeks prior to screening.
• Received chemotherapy and/or immunotherapy for a malignant tumor within 4 weeks prior to randomization, or are planned to receive such treatment during the study period; presence of a hematological malignancy not in complete remission; or a lung tumor with concurrent obstructive pneumonia.
• Presence of any concomitant disease that is expected to result in death within 12 weeks after randomization.
• Prior use of JAK inhibitors (e.g., Baricitinib), interleukin receptor inhibitors (e.g., Tocilizumab), or any investigational drug in another clinical trial, where the last dose was administered less than 5 half-lives before the first dose of the study drug in this trial.
• ALT) or AST > 3 times the upper limit of normal (ULN).
• eGFR < 30 mL/min/1.73 m² (calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula); however, patients undergoing dialysis may be included upon the investigator's assessment of their suitability for the trial.
• Presence of clinically significant abnormalities on ECG that may seriously affect subject safety, e.g., QTcF > 480 ms.
• Female subjects who are pregnant, lactating, or have a positive serum β-HCG pregnancy test.
• Presence of any severe systemic disease or clinical condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SR1375 capsule 3mg; SR1375 capsule 3mg quaque die(QD) orally with CAP regular treatments for 8 weeks	Drug: SR1375 capsule 3mg+regular treatments; SR1375 capsule 3mg QD orally+CAP regular treatments; Other Names: SR1375 capsule high dose+regular treatments
Experimental: SR1375 capsule 1mg; SR1375 capsule 1mg QD orally with CAP regular treatments for 8 weeks	Drug: SR1375 capsule 1mg+regular treatments; SR1375 capsule 1mg QD orally+CAP regular treatments; Other Names: SR1375 capsule medium dose+regular treatments
Experimental: SR1375 capsule 0.3mg; SR1375 capsule 0.3mg QD orally with CAP regular treatments for 8 weeks	Drug: SR1375 capsule 0.3mg+regular treatments; SR1375 capsule 0.3mg QD orally+CAP regular treatments; Other Names: SR1375 capsule low dose+regular treatments
Placebo Comparator: placebo capsule; Placebo capsule QD orally with CAP regular treatments for 8 weeks	Drug: Placebo capsule+regular treatments; Placebo capsule QD orally+CAP regular treatments

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
National Institute of Allergy and Infectious Diseases-Outcome Study (NIAID-OS) 8-point scale score	Change from baseline to Day 28 in NIAID-OS 8 scale score. NIAID-OS 8 scale ranges from 1 point (no hospitalization, no activity restrictions) to 8 points (death). The higher score means the worse outcome.	Up to Day 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects ≥ 2 points improvement in National Institute of Allergy and Infectious Diseases-Outcome Study (NIAID-OS) 8-point scale score	Subject proportion of ≥ 2 points improvement in NIAID-OS 8-point scale at Day 14 and Day 28	Up to Day 28
National Institute of Allergy and Infectious Diseases-Outcome Study (NIAID-OS) 8-point scale score	Change from baseline to Day 7 and Day 14 in NIAID-OS 8 scale score. NIAID-OS 8 scale ranges from 1 point (no hospitalization, no activity restrictions) to 8 points(death)，the higher score means the worse outcome.	Up to Day 14
All-cause mortality rate	The all-cause mortality rate at Day 28 and Day 56	Up to Day 56
Proportion of subjects with invasive mechanical ventilation, Extracorporeal Membrane Oxygenation(ECMO) or all-cause death.	Subjects proportions with invasive mechanical ventilation, ECMO or all-cause death at Day 28 and Day 56.	Up to Day 56
Proportion of subjects admitted in ICU or all-cause death	Proportion of subjects admitted in ICU or all-cause death at Day 28 and Day 56	Up to Day 56
Proportion of subjects ≤ 2 points in NIAID-OS 8-point scale	Proportion of subjects ≤ 2 points in NIAID-OS 8-point scale at Day 28 and Day 56	Up to Day 56
Survival days without invasive mechanical ventilation or ECMO	Survival days without invasive mechanical ventilation or ECMO within 28 and 56 days.	Up to Day 56
Survival days without ICU admission	Survival days without ICU admission within 28 and 56 days	Up to Day 56
Days of hospitalization	Days of hospitalization within 28 and 56 days	Up to Day 56
All-cause readmission rate	All-cause readmission rate within 56 days	Up to Day 56
Readmission rate due to pneumonia	Readmission rate due to pneumonia within 56 days	Up to Day 56
Partial Pressure of Oxygen(PaO2)/Fraction of Inspiration Oxygen(FiO2)	Change from baseline to Day 7 and Day 28 in PaO2/FiO2.	Up to Day 28

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
The item short from health survey (SF-36) score	Change from baseline to Day 28 and Day 56 in SF-36 score. SF-36 scores range from 0 to 100 and the higher score means the better condition.	Up to Day 56
Adverse events and serious adverse events	AE and SAE occurence and severity during the study	Up to Day 70
Pharmacokinetic (PK) parameter Cmax	Maximum plasma concentration (Cmax) will be calculated by PhoenixWinNonlin software (V8.0 or higher).	Up to Day 56
PK parameter Tmax	Time to maximum concentration (Tmax) will be calculated by PhoenixWinNonlin software (V8.0 or higher) .	Up to Day 56
PK parameter AUC0-t	Area under the concentration-time curve from 0 to the collection time t (AUC0-t) will be calculated by PhoenixWinNonlin software (V8.0 or higher).	Up to Day 56
PK parameter t1/2	Half-Life (t1/2) will be calculated by PhoenixWinNonlin software (V8.0 or higher).	Up to Day 56
PK parameter Vd/F	Apparent volume of distribution (Vd/F) will be calculated by PhoenixWinNonlin software (V8.0 or higher).	Up to Day 56
Pharmacodynamic (PD) parameter lipoprotein associated phospholipase A2 (Lp-PLA2) activity	PD parameter Lp-PLA2 activity will be tested in central laboratory.	Up to Day 56

Collaborators and Investigators

• Sponsor: Shanghai SIMR Biotechnology Co., Ltd.
• Investigators: Principal Investigator: Weimin Li, MD, West China Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 10, 2024
• Primary Completion (Estimated): October 15, 2025
• Study Completion (Estimated): October 30, 2025

Study Registration Dates

• First Submitted: August 19, 2024
• First Submitted That Met QC Criteria: August 27, 2024
• First Posted (Actual): August 29, 2024

Study Record Updates

• Last Update Posted (Actual): July 9, 2025
• Last Update Submitted That Met QC Criteria: July 7, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Keywords: Community acquired Pneumonia; SR1375
• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Respiratory Tract Diseases; Lung Diseases; Pneumonia
• Other Study ID Numbers: SR1375-204

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No